Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients

Rhea-AI Summary

Harrow (HROW) has expanded its VEVYE® Access for All (VAFA) program to include current Klarity-C Drops® patients, offering VEVYE at $59 per bottle. The expansion allows over 25,000 U.S. patients to convert their Klarity-C prescriptions to FDA-approved VEVYE, a cyclosporine ophthalmic solution 0.1% for dry eye disease treatment.

The program eliminates access barriers like prior authorization and reimbursement delays, while providing free home delivery and a money-back guarantee. Patients can choose between insurance coverage or Harrow's cash price. Klarity-C prescribers can transfer prescriptions through PhilRx's platform in under 5 minutes.

Positive

• Expansion to 25,000+ potential new customers for FDA-approved VEVYE
• Competitive pricing strategy at $59 per bottle
• Streamlined prescription transfer process (under 5 minutes)
• Elimination of insurance barriers and prior authorizations

Negative

• None.

Insights

Pharmaceutical Market Access Specialist

Harrow's expansion of its VEVYE Access for All program to include existing Klarity-C patients represents a strategic consolidation of their dry eye disease portfolio. By enabling the transition of 25,000+ patients from their compounded cyclosporine formulation to an FDA-approved alternative at the same $59 price point, Harrow is executing a calculated product migration strategy.

This move likely serves multiple purposes: 1) shifting patients from compounded to FDA-approved medications can improve reimbursement dynamics and potentially enhance margins, even at identical patient price points; 2) simplifying the prescription process by eliminating prior authorizations creates a compelling value proposition for prescribers; and 3) maintaining price parity ensures patient continuity while upgrading their therapy class.

The announcement represents an internal patient conversion rather than market expansion, but the strategy counters traditional pharmaceutical pricing models through transparent cash pricing and removal of insurance obstacles. While immediate revenue impact may be neutral if price points remain similar, the long-term benefits include streamlined operations, improved formulary positioning, and potentially enhanced brand loyalty across Harrow's ophthalmology portfolio.

Harrow's approach addresses the growing scrutiny of compounded medications while demonstrating commercial agility by coordinating across their prescription and compounding business units to optimize their product mix.

Existing Klarity-C Patients to Have Access to VEVYE for $59 Per Bottle

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an expansion of its VEVYE^® Access for All (“VAFA”) program to include patients currently prescribed Klarity-C Drops^®, a compounded cyclosporine 0.1% product manufactured and distributed by ImprimisRx^®, Harrow’s compounding subsidiary. Since its launch on March 17, 2025, VEVYE Access for All has simplified dry eye therapy for eligible patients by eliminating access barriers like prior authorization and reimbursement delays, providing free home delivery, and offering a no‑questions-asked, money-back guarantee.¹ The VEVYE Access for All program is flexible, allowing patients to choose to use their insurance coverage² or take advantage of Harrow’s affordable cash price.

As a result of today’s announcement, beginning immediately, more than 25,000 patients across the U.S. will be able to convert their Klarity-C prescriptions to VEVYE (cyclosporine ophthalmic solution) 0.1%, an FDA‑approved treatment for the signs and symptoms of dry eye disease, for $59 per bottle (including refills). As a part of this transition, Klarity-C prescribers have access to a prescription authorization platform to transfer Klarity-C prescriptions to PhilRx in a process that shouldn’t take more than 5 minutes.

“We are pleased to make VEVYE accessible and affordable to Klarity-C patients,” said Mark L. Baum, Chief Executive Officer of Harrow. “The secret to the success of VEVYE Access for All is simple: lower costs to patients and eliminate the requirement for prescribers to endure the burden of access obstacles like prior authorizations and step therapy. The result is twofold: dry eye patients receive what their doctor prescribes at an affordable price; and for doctors and their staff, choosing VEVYE is an absolute no‑brainer.”

“Pharmaceutical companies have long made promises to tackle the access barriers my colleagues and I encounter when advocating for our patients – especially in the realm of dry eye treatments. Harrow, a company that has consistently brought meaningful innovation to my practice, has delivered once again with VEVYE Access For All,” said Alice Epitropoulos, MD, FACS, Partner and Co-founder of the Eye Center of Columbus. “I often prescribed Klarity-C because it provided exceptional value to my patients, particularly those without insurance or with limited coverage. Now, being able to offer VEVYE at that same affordable price point to some of my dry eye disease patients – without the usual insurance hassles – is a game changer. This is true price transparency and accessibility that simplifies care and supports what matters most: better outcomes.”

“The value proposition here is undeniable,” added Mitchell Jackson, MD, Founder/Medical Director of Jacksoneye and a pioneer in refractive surgery and dry eye management. “My colleagues in ophthalmology and optometry already know about VEVYE’s extraordinary clinical benefits. But how often do we see a pharmaceutical company actually lower costs and pass those savings directly to the patients – all while removing the insurance hurdles that have burdened our practices? Only Harrow. No prior authorizations or step therapy requirements, no surprise bills – just straightforward, reliable access to an excellent medication. It’s the kind of model our healthcare system should be moving toward.”

Klarity-C prescribers who have questions regarding the transition to VEVYE or the VEVYE Access for All program may call (855) 977-0975 or e-mail mdsupport@usephil.com for further assistance.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks, including litigation matters, and other uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC. Such documents may be read free of charge on the SEC’s web site at sec.gov. Undue reliance should not be placed on forward‑looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

____________________

1 This offer is available on one fill only and is valid only for eligible patients paying cash who do not have commercial or government insurance. This offer is not valid for patients with government insurance, including, but not limited to, Medicaid or Medicare. Contact Harrow at 833-443-7769 for information on our money-back guarantee.

2 For patients whose prescriptions are covered by commercial insurance, use of this program may reduce their VEVYE copayment to as little as $0. For patients whose prescriptions are not covered by commercial insurance, this program may reduce their cost for prescriptions to as little as $59. For full terms and conditions, please visit vevye.com/accessforall.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250410793815/en/

Investors:

Jamie Webb, Director of Communications and Investor Relations

Harrow, Inc.

jwebb@harrowinc.com

615-733-4737

Media:

Silvana Guerci-Lena

Powers & Company

silvana@powers-co.com

508-808-8993

Source: Harrow, Inc.

FAQ

What is the cost of VEVYE under Harrow's Access for All program for Klarity-C patients?

VEVYE costs $59 per bottle, including refills, for Klarity-C patients under the Access for All program.

How many patients can potentially convert from Klarity-C to VEVYE (HROW)?

Over 25,000 patients across the U.S. are eligible to convert their Klarity-C prescriptions to VEVYE.

What benefits does VEVYE Access for All program offer to patients?

The program offers free home delivery, no prior authorization requirements, elimination of reimbursement delays, and a money-back guarantee.

How long does it take for doctors to transfer Klarity-C prescriptions to VEVYE?

Doctors can transfer Klarity-C prescriptions to VEVYE through PhilRx's platform in less than 5 minutes.

Does VEVYE Access for All program allow patients to use insurance coverage?

Yes, patients can choose to either use their insurance coverage or opt for Harrow's affordable cash price.